Advances in cell and gene therapy最新文献

{"title":"Genetics, prognosis, and transplantation for myelofibrosis","authors":"H. Joachim Deeg,&nbsp;Rachel Salit,&nbsp;Bart L. Scott,&nbsp;Janghee Woo","doi":"10.1002/acg2.24","DOIUrl":"10.1002/acg2.24","url":null,"abstract":"<p>Primary myelofibrosis (PMF), polycythemia vera (PV), and essential thrombocythemia (ET) are chronic disorders that may extend over years or decades. Therapy tends to be conservative, but once marrow fibrosis and peripheral cytopenias become the dominant characteristics, prognosis is poor. Hematopoietic cell transplantation (HCT) is the only treatment with curative potential, leading to survival in remission in 35%-70% of patients. However, HCT is associated with risks, and despite the development of numerous risk scoring systems, optimal timing of HCT remains controversial. The identification of “driver mutations” in <i>JAK2, MPL1,</i> and <i>CALR,</i> and prognostically relevant additional mutations, may assist in the decision-making process. While patients with type 1 <i>CALR</i> mutations generally have a superior prognosis, absence of all driver mutations is associated with inferior outcome. Mutations in <i>ASXL1, SRSF2, IDH1/2,</i> and <i>EZH2</i> are linked to more rapid disease progression and, along with biallelic <i>TP53</i> mutations, leukemic transformation. The strongest risk factor is the presence of <i>multiple mutations</i>. By MIPSS70 criteria, considering mutations, median survival was 27 years for the best risk group, but 2.3 years for the highest-risk group. The presence of nondriver mutations, particularly in the absence of <i>CALR</i> mutations, and association with adverse cytogenetics, should lead to consideration of HCT. But the role of mutations has to be assessed in the context of the overall presentation. Unfortunately, risk factors that affect the natural history of the disease also impact post-HCT outcome. Needed are innovative transplant strategies, also including pre-HCT and post-HCT adjuvant therapy.</p>","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.24","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41937476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dawn of chimeric antigen receptor T cell therapy in non-Hodgkin Lymphoma","authors":"Karlo Perica,&nbsp;M. Lia Palomba,&nbsp;Renier J. Brentjens","doi":"10.1002/acg2.23","DOIUrl":"10.1002/acg2.23","url":null,"abstract":"<p>Two Chimeric Antigen Receptor (CAR) T-cell therapies are now approved for the treatment of relapsed and refractory large cell lymphomas, with many others under development. The dawn of CAR T-cell therapy in non-Hodgkin Lymphoma (NHL) has been characterized by rapid progress and high response rates, with a subset of patients experiencing durable benefit. In this review, we describe commercially available and investigational CAR T-cell therapies, including product characteristics and clinical outcomes. We review patient selection, with an emphasis on sequencing cell therapies including autologous and allogeneic stem cell transplantation. Finally, we discuss durability of response, highlighting mechanisms of escape and investigational approaches to prevent and treat relapse after CAR T cell therapy.</p>","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.23","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38573735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Return of gemtuzumab ozogamicin in acute myeloid leukemia—Is it for everyone with CD33+ disease?","authors":"Prajwal Boddu,&nbsp;Farhad Ravandi","doi":"10.1002/acg2.21","DOIUrl":"10.1002/acg2.21","url":null,"abstract":"<p>Mechanism of action of GO in AML</p><p>Illustrator credit: Claudia Bentley\u0000\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </p>","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.21","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42836187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in transplantation for lymphomas resulting from CIBMTR lymphoma working committee's research portfolio: A five-year report (2013-2018)","authors":"Mehdi Hamadani","doi":"10.1002/acg2.17","DOIUrl":"10.1002/acg2.17","url":null,"abstract":"<p>The Center for International Blood and Marrow Transplant Research (CIBMTR) is a research collaboration between the National Marrow Donor Program (NMDP)/Be The Match and the Medical College of Wisconsin (MCW). The CIBMTR collaborates with the global scientific community to advance hematopoietic cell transplantation (HCT) and cellular therapy worldwide to increase survival and enrich quality of life for patients. The observation research program within CIBMTR is organized into 15 working committees. This review is aiming to highlight the observational research studies published by the CIBMTR Lymphoma Working committee over the last 5 years (2013-18) and to summarize how these studies have impacted the field by helping inform clinical practice in scenarios where prospective data from high quality randomized trials were not available or where owing to the rarity of a particular transplant indication such data were unlikely to be generated, outside the setting of a large observational research database. The salient findings reviewed include; (a) studies supporting role of autologous HCT in diffuse large B-cell lymphoma (DLBCL) patients with sensitive relapse of disease within 1 year of diagnosis, (b) role of autologous HCT vs allogeneic HCT in follicular lymphoma patients with early therapy failure, (c) prognostic scoring system development for classical Hodgkin lymphoma and DLBCL patients with prior autograft failure, (d) defining the role of alternative donor transplantation in lymphomas, (e) evaluating appropriate conditioning regimens for HCT in lymphoma, and (f) outcomes of HCT in rare lymphoid malignancies.</p>","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.17","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25469499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mesenchymal stromal cell infusions for acute graft-versus-host disease: Rationale, data, and unanswered questions","authors":"Amara Seng,&nbsp;Neil Dunavin","doi":"10.1002/acg2.14","DOIUrl":"10.1002/acg2.14","url":null,"abstract":"<p>Mesenchymal stem/stromal cells (MSCs) infusions are a promising investigational treatment strategy for steroid-refractory acute graft-versus-host disease (GVHD). Herein we describe the rationale for their use in acute GVHD, the clinical data reported from animal and human studies to date, and we highlight recent areas of research and investigation that provide the basis for improvements in the next generation of studies.</p>","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.14","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49619658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HLA typing—A case-based approach to donor selection","authors":"Neema P. Mayor,&nbsp;Bronwen E. Shaw","doi":"10.1002/acg2.16","DOIUrl":"10.1002/acg2.16","url":null,"abstract":"<p>In the early years of hematopoietic cell transplantation (HCT), matching of patients and donors was poorly understood and complications related to genetic (especially HLA) mismatching were profound, resulting in a very high incidence of fatal graft-versus-host disease (GVHD). This essentially limited the choice of a donor to a sibling, and as the understanding of HLA improved, defined the donor as an HLA-identical sibling. As patient outcomes improved, the use of an unrelated donor (URD) became more common. Later, with the advent of URD registries and improved HLA typing techniques, the use of an URD overtook that of an HLA-identical sibling in frequency both in Europe and in the United States (US). Increasing confidence in our ability to manage and prevent the immune complications of HCT led to the use of HLA-mismatched donors being expanded, in the setting of umbilical cord blood (UCB) and haploidentical transplantation. In 2018, it is unusual for a patient not to go to transplant due to the lack of a suitable donor option. In this manuscript, we describe the impact of genetic factors, in particular HLA, and the technologies for typing these, on the outcomes of HCT. We highlight both well-accepted donor selection practices and newer or more controversial advances in donor selection.</p>","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.16","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50822197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Method comparison study of peripheral blood CD34+ count performed on an Abbott CELL-DYN Sapphire hematology analyzer versus flow cytometry reference procedure (modified ISHAGE)","authors":"Scott T. Avecilla,&nbsp;Cheryl Goss,&nbsp;Steven M. Marionneaux,&nbsp;Donald R. Wright,&nbsp;Tyler D. Leiva,&nbsp;Jo-ann Tonon,&nbsp;Katherine M. Smith,&nbsp;Peter Maslak","doi":"10.1002/acg2.15","DOIUrl":"10.1002/acg2.15","url":null,"abstract":"<p>CD34⁺ cell enumeration is a critical parameter used to determine the timing of apheresis collections of hematopoietic progenitor cell products (HPC(A)). Automated hematology analyzers equipped with flow cytometry capabilities may be a solution to the problem of limited access to standard flow cytometry testing. We compared CD34⁺ cell enumeration using a reference flow cytometry procedure employing modified International Society of Hematotherapy and Graft Engineering (ISHAGE) analysis with a hematology analyzer/flow cytometer hybrid (CELL DYN (CD)Sapphire) using a sequential gating analysis designed to emulate the ISHAGE gating strategy. CD34⁺ cell values obtained from the ISHAGE and CD Sapphire analysis was plotted and compared in a linear regression analysis which showed a high degree of correlation (<i>R</i>² = 0.96). No statistically significant (<i>P</i> = 0.53) differences in CD34⁺ cell enumeration values were observed between the flow cytometer and automated hematology analyzer using manual analysis schema. We have demonstrated that an automated hematology analyzer equipped with a flow module can provide CD34⁺ cell enumeration results in the peripheral blood for clinical decision algorithms without the need for a dedicated flow cytometry laboratory.</p>","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.15","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37057791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Double-hit and double-expressor B-cell lymphomas: Current treatment strategies and impact of hematopoietic cell transplantation","authors":"Akihiro Ohmoto,&nbsp;Shigeo Fuji","doi":"10.1002/acg2.13","DOIUrl":"10.1002/acg2.13","url":null,"abstract":"<p>High-grade B-cell lymphoma with rearrangement of <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> (double-hit lymphoma: DHL) was newly categorized as a subtype in the 2016 revision of the WHO classification of lymphoid neoplasms. DHL is a rare entity accounting for &lt;10% of DLBCL and clinical data of DHL cases are still limited. Standard rituximab-incorporated chemotherapy was reported to be underpowered for this intractable disease, and some promising results with intensified regimen including dose-adjusted EPOCH-R (rituximab, etoposide, vincristine, adriamycin, cyclophosphamide, and prednisone) have been emerging. The benefit of intensified regimen for DHL patients should be determined in randomized trials. The role of consolidative autologous (auto) hematopoietic cell transplantation (HCT) for newly diagnosed cases has been also undetermined. In regards to salvage chemotherapy followed by auto-HCT for chemotherapy-sensitive relapsed cases, the prognosis seems to be unsatisfactory in patients with DHL, and novel treatment strategies to incorporate effective salvage, auto-HCT and maintenance treatment after auto-HCT are warranted. Clinical application of allogeneic (allo)-HCT has not been established in newly diagnosed and refractory/relapsed (ref/rel) cases. Recently, favorable survival data of allo-HCT for ref/rel DHL was reported. To clarify the indication of various treatment strategies, larger-scaled studies or new prognostic models for DHL are required. As another topic, clinical investigation of several novel agents such as BCL2 inhibitor is conducted along with DLBCL. Here, we summarize the data relating to DHL focusing on the application of HCT, and also discuss about the combination therapy using novel agents in the setting of HCT.</p>","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.13","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47596842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The science of evidence synthesis in hematopoietic stem-cell transplantation: Meta-analysis and quality assessment","authors":"Nico Gagelmann,&nbsp;Nicolaus Kröger","doi":"10.1002/acg2.12","DOIUrl":"10.1002/acg2.12","url":null,"abstract":"<p>A meta-analysis is a statistical analysis that combines the results of multiple scientific studies. After being introduced in the 1970s, meta-analysis significantly influenced decision making in many scientific disciplines, helping to establish evidence-based medicine and to resolve seemingly contradictory research outcomes. Since the first meta-analysis on autologous hematopoietic stem-cell transplantation (HSCT) was published in 1989, the implementation of the method into research and clinical guidance in hematopoietic stem-cell transplantation faced challenges specific to the field. Here, we take the opportunity provided by the recent fortieth anniversary of meta-analysis to reflect on the accomplishments, limitations, and developments in the field of research synthesis in HSCT by summarizing the main methodological features of meta-analysis and its extensions, and by exemplifying the power and evolution of evidence synthesis in HSCT.</p>","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.12","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47629753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAR T cells targeting αvβ3 integrin are effective against advanced cancer in preclinical models","authors":"Lars Wallstabe,&nbsp;Andreas Mades,&nbsp;Silke Frenz,&nbsp;Hermann Einsele,&nbsp;Christoph Rader,&nbsp;Michael Hudecek","doi":"10.1002/acg2.11","DOIUrl":"https://doi.org/10.1002/acg2.11","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>Integrins are heterodimeric receptors that convey cell-to-cell and cell-to-matrix interactions. Integrin α_vβ₃ is expressed in several tumor entities including melanoma, glioblastoma, breast, pancreatic, and prostate cancer, where it promotes tumor cell survival and metastasis. Here, we generated α_vβ₃-specific chimeric antigen receptor (CAR) T cells and analyzed their antitumor function in preclinical models in vitro and in vivo. α_vβ₃-CARs comprising a super-humanized hLM609 targeting domain with either high or low affinity (hLM609v7, <i>K</i>_d = 3 nM vs hLM609v11, <i>K</i>_d = 160 nM) and equipped with either a long or a short IgG4-Fc extracellular spacer (229 vs 12 amino acids) were expressed in CD8⁺ and CD4⁺ T cells through lentiviral transduction. α_vβ₃-CAR T cells eliminated α_vβ₃-positive tumor cells rapidly and specifically, produced IFN-γ and IL-2 (CD4⁺ &gt; CD8⁺) and exhibited productive proliferation. In vitro, we observed the strongest reactivity with the higher affinity hLM609v7 α_vβ₃-CAR in the short spacer configuration, consistent with the tumor membrane-distal localization of the hLM609 epitope. In a murine xenograft model of metastatic A-375 melanoma, the strongest antitumor effect was mediated by the lower affinity hLM609v11 α_vβ₃-CAR. Notably, a single administration of hLM609v11 α_vβ₃-CAR T cells was able to induce complete elimination of melanoma lesions, leading to long-term tumor-free survival. These data establish α_vβ₃ integrin as a novel target for CAR T-cell immunotherapy and affirm our previous notion that binding domain affinity and spacer length can be calibrated to augment CAR reactivity. α_vβ₃-CAR T cells have therapeutic potential in several prevalent solid tumors, including melanoma and triple-negative breast cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.11","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71957751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}